Cargando…

Retraction: A deep insight into CAR-T cell therapy in non-Hodgkin lymphoma: application, opportunities, and future directions

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507392/ https://www.ncbi.nlm.nih.gov/pubmed/37731486 http://dx.doi.org/10.3389/fimmu.2023.1285110

Ejemplares similares

A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions
por: Marofi, Faroogh, et al.
Publicado: (2021)

Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma
por: Caimi, Paolo F., et al.
Publicado: (2021)

Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma
por: Jackson, Zachary, et al.
Publicado: (2020)

CAR-T Cell Therapy in the Treatment of Pediatric Non-Hodgkin Lymphoma
por: Ostojska, Magdalena, et al.
Publicado: (2023)

CAR-T Cell Therapy for Classical Hodgkin Lymphoma
por: Katsin, Mikalai, et al.
Publicado: (2023)

Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy
por: Fang, Penny Q., et al.
Publicado: (2021)

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
por: Zhang, Xiaomin, et al.
Publicado: (2022)

The Past, Present, and Future of Non-Viral CAR T Cells
por: Moretti, Alex, et al.
Publicado: (2022)

T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions
por: Russler-Germain, David A., et al.
Publicado: (2023)

The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
por: Meier, Jeremy A., et al.
Publicado: (2022)

The Transferrin Receptor-Directed CAR for the Therapy of Hematologic Malignancies
por: Guo, Zilong, et al.
Publicado: (2021)

Case report: simultaneous occurrence of multiple myeloma and non-Hodgkin lymphoma treated by CAR T therapy
por: Li, Tongjuan, et al.
Publicado: (2020)

Genomic crossroads between non-Hodgkin’s lymphoma and common variable immunodeficiency
por: Guevara-Hoyer, Kissy, et al.
Publicado: (2022)

Extracellular vesicles as biomarkers for AIDS-associated non-Hodgkin lymphoma risk
por: Martínez, Laura E., et al.
Publicado: (2023)

Current and Future Role of Medical Imaging in Guiding the Management of Patients With Relapsed and Refractory Non-Hodgkin Lymphoma Treated With CAR T-Cell Therapy
por: Vercellino, Laetitia, et al.
Publicado: (2021)

Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future
por: Sorge, Caryn E., et al.
Publicado: (2016)

The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology
por: Mohseni, Yasmin R., et al.
Publicado: (2020)

CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future
por: Lin, Ya-Jui, et al.
Publicado: (2022)

Bright future or blind alley? CAR-T cell therapy for solid tumors
por: Zhang, Kai, et al.
Publicado: (2023)

Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma
por: Wiedmeier, Julia E., et al.
Publicado: (2021)

Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma
por: Wiedmeier-Nutor, Julia Erin, et al.
Publicado: (2022)

Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma
por: Wiedmeier-Nutor, Julia E., et al.
Publicado: (2023)

The Insights of Head and Neck Non-Hodgkin Lymphoma
por: Wan Abdul Rahman, Wan Faiziah, et al.
Publicado: (2020)

Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells
por: Hiltensperger, Michael, et al.
Publicado: (2023)

Next generations of CAR-T cells - new therapeutic opportunities in hematology?
por: Tomasik, Jaromir, et al.
Publicado: (2022)

Salmonella Immunotherapy Improves the Outcome of CHOP Chemotherapy in Non-Hodgkin Lymphoma-Bearing Mice
por: Bascuas, Thais, et al.
Publicado: (2018)

Update for Advance CAR-T Therapy in Solid Tumors, Clinical Application in Peritoneal Carcinomatosis From Colorectal Cancer and Future Prospects
por: Qian, Siyuan, et al.
Publicado: (2022)

Gene-Edited Interleukin CAR-T Cells Therapy in the Treatment of Malignancies: Present and Future
por: Zhang, Zhengchao, et al.
Publicado: (2021)

Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer
por: Hu, Chunmei, et al.
Publicado: (2023)

Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations
por: Zhang, Qi, et al.
Publicado: (2023)

Ibrutinib improves the efficacy of anti‐CD19‐CAR T‐cell therapy in patients with refractory non‐Hodgkin lymphoma
por: Liu, Meijing, et al.
Publicado: (2021)

Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma
por: Saifi, Omran, et al.
Publicado: (2023)

Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy
por: Kilgour, Marisa K., et al.
Publicado: (2023)

Prognostic value of the albumin-bilirubin score in patients with non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis
por: Cheng, Wanying, et al.
Publicado: (2023)

Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges
por: Makita, Shinichi, et al.
Publicado: (2019)

Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy
por: Grover, Natalie S., et al.
Publicado: (2015)

FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas
por: Barrington, Sally F., et al.
Publicado: (2017)

CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies
por: Antonucci, Laura, et al.
Publicado: (2022)

Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia
por: Rozenbaum, Meir, et al.
Publicado: (2020)

Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma
por: Zhang, Wenqi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7uqgr530296rtkglqsuqcg996l